Hanmi Pharmaceutical expects U.S. FDA approval for 2 new drugs

Hanmi Pharmaceutical expects U.S. FDA approval for 2 new drugs

Condividi: 18 gennaio 2021 SEOUL, South Korea, Jan. 18, 2021 /PRNewswire/ — Hanmi Pharmaceutical Co., Ltd. plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields.
In particular, two new drugs developed by Hanmi Pharmaceutical Co., Ltd. are expected to be approved by the U.S. FDAleggi di più…

Hanmi presents solution package strategy to potentially overcome COVID 19 at the 39th JP Morgan Healthcare Conference

Hanmi presents solution package strategy to potentially overcome COVID-19 at the 39th JP Morgan Healthcare Conference

Condividi: 13 gennaio 2021 Hanmi Pharmaceutical Co., Ltd. develops a full package strategy to potentially handle the COVID-19, including the mass production of nucleic acid vaccines (DNA/mRNA vaccine)
Recently releases Hanmi Cold-Mask™(nasal spray) and on preparation to release COVID-19 & Influenza dual diagnostic kit
SEOUL, South Korea, Jan. 12, 2021 /PRNewswire/ — Hanmi Pharmaceutical Co., Ltd., announced “endless challenges and new commitments for the pharmaceutical industry” leggi di più…